Prolia (Denosumab) Cost in Nevada 2026: Prices, Insurance, and Savings

What Does Prolia (Denosumab) Actually Cost in Nevada?

The Amgen wholesale acquisition cost (WAC) for a single 60 mg prefilled syringe of Prolia is approximately $1,500, and Nevada retail pharmacies closely mirror that figure for cash-pay patients in 2026. Because denosumab is dosed every six months, the annual cash price sits near $3,000 before any discounts or insurance adjustments.

That $1,500 per-dose number represents the list price. Few patients pay the full amount. Commercial insurance, Medicare Part B, and manufacturer programs all reduce out-of-pocket spending for most people. A 2020 analysis in the Journal of Managed Care & Specialty Pharmacy found that real-world patient costs for denosumab varied from $0 to over $1,000 per dose depending on plan design and copay assistance enrollment [1]. Nevada follows the same pattern: what you actually pay depends on your coverage tier, your pharmacy benefit versus medical benefit structure, and whether you qualify for Amgen's savings programs.

Pricing also differs between clinic-administered and pharmacy-dispensed routes. When Prolia is given in a physician's office, it typically bills under the medical benefit (Medicare Part B or the medical side of commercial insurance). When dispensed through a specialty pharmacy for home injection, it may bill under the pharmacy benefit. This distinction matters in Nevada because medical-benefit coverage often carries different cost-sharing rules than pharmacy-benefit coverage [2].

Nevada Medicaid and Prolia: What You Need to Know

Nevada Medicaid does not cover Prolia as of 2026. This is a significant gap for low-income residents managing osteoporosis. Nevada's Medicaid preferred drug list (PDL) excludes denosumab, meaning fee-for-service Medicaid beneficiaries cannot obtain it through standard channels.

For Medicaid enrollees who need an antiresorptive agent, oral bisphosphonates such as alendronate (generic Fosamax) and risedronate remain the covered first-line options. These drugs have strong trial evidence: the Fracture Intervention Trial (FIT) demonstrated that alendronate reduced hip fracture risk by 51% over three years in women with existing vertebral fractures [3]. Bisphosphonates are not identical to denosumab in mechanism or efficacy profile, but they represent the available Medicaid-covered alternative in Nevada.

Patients whose physicians believe denosumab is medically necessary despite Medicaid exclusion can request a prior authorization exception. Approval rates for these exceptions vary. The Nevada Department of Health and Human Services reviews exception requests on a case-by-case basis, and documentation of bisphosphonate intolerance, contraindication, or treatment failure strengthens the request.

If you are on Nevada Medicaid and have been denied Prolia coverage, a formal appeal with supporting bone mineral density (BMD) data and a letter from your prescribing physician is the recommended next step.

Medicare Part B Coverage for Prolia in Nevada

Medicare Part B generally covers Prolia when administered in a healthcare provider's office. This is the most common reimbursement pathway for Nevada residents aged 65 and older receiving denosumab for postmenopausal osteoporosis.

Under Part B, patients typically owe 20% coinsurance after meeting the annual deductible ($257 in 2026). That means a Part B beneficiary without supplemental coverage could pay around $300 per injection out of pocket. Medigap plans (Medicare Supplement Insurance) often cover this 20% coinsurance, reducing the cost to $0 at the point of care.

The FREEDOM trial (N=7,868), published in the New England Journal of Medicine, established the fracture-reduction efficacy that supports Medicare coverage. Over 36 months, denosumab 60 mg every six months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo [4]. The FREEDOM Extension study followed participants for up to 10 years and showed sustained fracture risk reduction with continued treatment [5].

Medicare Advantage plans in Nevada (offered by UnitedHealthcare, Humana, Anthem, and others) also cover Prolia, though formulary placement, step-therapy requirements, and copay amounts differ by plan. Check your specific plan's evidence of coverage document or call the number on your member ID card to confirm your cost.

Commercial Insurance Coverage Across Nevada

Most major commercial insurers operating in Nevada cover Prolia with prior authorization. This includes plans from Anthem Blue Cross Blue Shield, UnitedHealthcare, Aetna, Cigna, and Health Plan of Nevada (HPN). Coverage typically requires documentation that the patient meets FDA-approved indications and, in some cases, has tried or cannot tolerate an oral bisphosphonate first.

Step therapy is common. Many plans require a trial of alendronate or risedronate before approving denosumab. The American Association of Clinical Endocrinologists (AACE) 2020 guidelines recognize denosumab as a first-line option for postmenopausal osteoporosis, particularly in patients at high fracture risk [6]. Citing these guidelines in the prior authorization request may help bypass step-therapy requirements.

Copay amounts under commercial plans range widely. With a specialty-tier placement, patients might face copays of $100 to $500 per injection before applying manufacturer assistance. Some plans classify Prolia under the medical benefit when office-administered, which can result in lower cost-sharing than specialty pharmacy dispensing.

"Denosumab should be considered a first-line therapy for patients with osteoporosis who are at high risk for fracture, including those with a T-score of -2.5 or below at the lumbar spine or femoral neck," according to the AACE/ACE 2020 Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis [6].

The Amgen Savings Card: How It Works in Nevada

Amgen offers a copay assistance program called Amgen Assist for commercially insured patients prescribed Prolia. Eligible patients can reduce their out-of-pocket cost to as little as $0 per injection, with the card covering up to a set annual maximum (currently up to $1,800 per year for most enrollees).

Eligibility rules are straightforward. You must have commercial insurance that covers Prolia, you must not be enrolled in a government-funded program (Medicare, Medicaid, Tricare, VA), and you must be a resident of the United States. Nevada patients who fill these criteria can enroll online at the Amgen Assist website or through their prescriber's office.

The card works at the point of sale. Your pharmacy or physician's office bills your insurance first, and the savings card covers the remaining copay or coinsurance up to the program's annual cap. For a patient with a $300 copay per injection, the card eliminates that cost for both doses in a year.

There are limitations. The program does not apply to government insurance beneficiaries. Medicare patients are specifically excluded, which is a notable gap given that the majority of Prolia users are over 65. Medicare patients should instead explore State Pharmaceutical Assistance Programs (SPAPs) or nonprofit foundations like the HealthWell Foundation and the Patient Access Network (PAN) Foundation, both of which have periodically offered osteoporosis-specific funds.

Compounded Denosumab in Nevada: Legality and Access

Compounded denosumab is legally available in Nevada through licensed 503A compounding pharmacies. A 503A pharmacy compounds medications pursuant to individual patient prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act [7].

This is a meaningful access point. Compounded versions can cost significantly less than brand Prolia. However, compounded biologics carry important caveats. Denosumab is a monoclonal antibody, and compounding a biologic is not the same as compounding a small-molecule drug like liothyronine or testosterone. The FDA has expressed concern about the quality and sterility of compounded biologics, and compounded denosumab does not undergo the same regulatory review as Amgen's FDA-approved product [7].

Nevada's Board of Pharmacy regulates 503A pharmacies operating in the state. Patients considering compounded denosumab should verify that the pharmacy holds a current Nevada Board of Pharmacy license, follows USP 797 and USP 800 sterile compounding standards, and provides certificates of analysis for finished preparations.

Your prescribing physician must write a patient-specific prescription for compounded denosumab. The prescription cannot simply say "Prolia." It should specify denosumab 60 mg/mL for subcutaneous injection. Not all physicians are comfortable prescribing compounded biologics, and this is a conversation to have directly with your provider.

"Patients should be aware that compounded drugs are not FDA-approved and may differ from commercially available products in terms of potency, purity, and sterility," states the FDA's guidance on compounded biologics [7].

Telehealth Prescribing of Prolia in Nevada

Nevada permits telehealth prescribing of denosumab. A physician licensed in Nevada can evaluate a patient via video or audio visit, review bone density results and lab work, and write a prescription for Prolia or compounded denosumab without an in-person visit.

This matters for access. Nevada is geographically large, and residents in rural counties (Elko, Humboldt, Pershing, Nye) may live hours from the nearest endocrinologist or rheumatologist. Telehealth removes the travel barrier for the prescribing visit, though patients still need an in-person appointment or home health visit for the actual injection if they are not self-injecting.

Nevada Assembly Bill 292, enacted in 2021, expanded telehealth parity requirements for commercial insurers in the state, mandating that telehealth visits be reimbursed at the same rate as in-person visits for the same service [8]. This means your insurer cannot deny coverage of a telehealth consultation for osteoporosis management solely because it was conducted remotely.

HealthRX offers telehealth consultations with Nevada-licensed physicians who can evaluate your bone health, order or review DXA scans, and prescribe denosumab if appropriate. The process includes lab review, a FRAX fracture risk assessment, and a treatment plan discussion.

Discount Programs and Patient Assistance Beyond Insurance

Several discount and assistance pathways exist for Nevada patients who face high out-of-pocket Prolia costs.

Amgen's Safety Net Foundation provides free Prolia to uninsured patients who meet income eligibility requirements (generally household income at or below 300% of the federal poverty level). Application requires proof of income and a prescription from your physician. Processing takes two to four weeks in most cases.

GoodRx and RxSaver discount cards do not typically produce meaningful savings on Prolia because it is a specialty injectable, but they are worth checking. Specialty pharmacy discount programs occasionally offer lower pricing than standard retail.

The NeedyMeds database (needymeds.org) aggregates current patient assistance programs and can identify active osteoporosis-specific funds. Funds open and close throughout the year based on donations, so checking quarterly is advisable.

For veterans, the VA health system covers denosumab for eligible beneficiaries. Nevada has VA medical centers in Las Vegas (VA Southern Nevada Healthcare System) and Reno (VA Sierra Nevada Healthcare System). VA formulary coverage of Prolia does not require the same prior authorization hurdles that commercial plans impose.

Comparing Prolia Costs to Alternative Osteoporosis Treatments in Nevada

Prolia is not the only option. Understanding how its cost compares to alternatives helps inform treatment decisions.

Generic alendronate (70 mg weekly oral tablet) costs $4 to $15 per month at Nevada pharmacies. It is the cheapest antiresorptive option and is covered by virtually every insurance plan, including Nevada Medicaid. The FIT trial showed alendronate reduces vertebral fracture risk by 47% over three years [3].

Zoledronic acid (Reclast), given as an annual IV infusion, lists at approximately $1,200 to $1,500 per infusion. The HORIZON Key Fracture Trial (N=7,765) demonstrated a 70% reduction in vertebral fractures and a 41% reduction in hip fractures over three years [9]. Annual dosing means lower total cost compared with every-six-month Prolia dosing in some scenarios. Medicare Part B covers zoledronic acid infusions.

Teriparatide (Forteo) and abaloparatide (Tymlos), both anabolic agents, cost $3,000 to $4,000 per month at list price. These are typically reserved for patients with very high fracture risk or those who have failed antiresorptive therapy.

Romosozumab (Evenity), a dual-action agent, lists at approximately $1,825 per monthly dose for 12 months. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48% compared with alendronate alone over 24 months [10]. It is the most expensive first-line option but is time-limited to one year of treatment.

The choice between these agents depends on fracture risk severity, prior treatment history, comorbidities, and cost considerations. For a Nevada patient with commercial insurance and Amgen Assist eligibility, Prolia may cost $0 out of pocket. For a Nevada Medicaid patient, generic alendronate at $4 per month is the practical starting point.

When to Start and How to Stay on Denosumab Safely

Discontinuation of denosumab carries a documented rebound risk. The FREEDOM Extension data showed that patients who stopped denosumab after long-term use experienced rapid bone mineral density loss and an increased rate of multiple vertebral fractures within 12 to 18 months of the last dose [5]. The Endocrine Society recommends transitioning to a bisphosphonate (oral or IV) after stopping denosumab to prevent this rebound effect [11].

This rebound risk makes cost-driven interruptions dangerous. If you start Prolia, you need a plan to continue it or transition off it safely. Skipping doses because of cost or insurance changes is not a neutral decision. Before starting treatment, confirm that your coverage and budget can sustain the every-six-month schedule, or discuss a transition-to-bisphosphonate protocol with your physician in advance.

Baseline labs before starting denosumab should include serum calcium, 25-hydroxyvitamin D, and a comprehensive metabolic panel. Hypocalcemia is the most clinically significant adverse effect, occurring in 0.4% of patients in the FREEDOM trial but at higher rates in patients with chronic kidney disease (CKD stage 4-5) [4]. Vitamin D levels should be at or above 30 ng/mL before the first injection. Supplementation with calcium 1,000 mg and vitamin D 800 to 1,000 IU daily is standard practice during denosumab therapy per the FDA label [12].